Scienture Holdings, Inc.
SCNXHealthcareNASDAQPharmaceutical Retailers
Scan Results
Daily timeframeScienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. Valued at $15.8M, SCNX is a micro-cap name in its sector. The company develops SCN-102, an oral liquid formulation of losartan potassium that is in phase 1 for the treatment of hypertension, diabetic nephropathy, and reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy; and SCN-104, a multi-dose dihydroergotamine mesylate (DHE) injection pen.
Market Cap
$15.8M
Beta
—
P/E (TTM)
—
P/E (Fwd)
-6.48
EPS (TTM)
$-2.25
EPS (Fwd)
$-0.06
ROE
-56.6%
ROA
-10.8%
Cash
$3.5M
Total Debt
$10,004
Free CF
-$815,500
52W Change
-82.3%
Annual Financials
Cash vs Debt
Where SCNX stands vs its 150-day and 200-day moving averages
As of the July 15, 2026 close, SCNX finished 9.30% below its 150-day moving average ($0.43) and 23.53% below its 200-day moving average ($0.51). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is SCNX overbought or oversold?
At the July 15, 2026 close, SCNX's RSI(14) was 52.3, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $3.5M in cash comfortably exceeding the $10K debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$816K. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -56.6%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $10.3M (2022) to $432K (2025), a 96% decline worth watching.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Scienture Holdings, Inc.'s trajectory.